A Pilot Study Comparing Neoadjuvant and Adjuvant GVAX vs a Mutated KRAS Peptide Vaccine Given With Anti-PD-1 and Anti-CD137 for the Treatment of Surgically Resectable Pancreatic Adenocarcinoma
Latest Information Update: 24 Jan 2025
Price :
$35 *
At a glance
- Drugs AGEN 2373 (Primary) ; Balstilimab; Cyclophosphamide; Poly ICLC; Tumour cell vaccine-GVAX
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions
- 24 Jan 2025 New trial record